Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ADmit Therapeutics
Esplugues de Llobregat, Catalonia, Spainadmit-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ADmit Therapeutics has developed the MAP‑AD®/ADmit Test, an innovative blood-based in vitro diagnostic that predicts the progression from mild cognitive impairment to Alzheimer's dementia. The test analyzes mitochondrial DNA methylation patterns using next-generation sequencing and incorporates genetic and clinical risk factors. It enables earlier intervention by identifying at-risk individuals before classical protein aggregates appear. The technology has received European funding support and key regulatory certifications in Spain.
- Therapeutic areas
- Neurology
- Modalities
- Diagnostic test (IVD)Biomarkers analysisEpigenetic analysis (methylation biomarkers)Next generation sequencing platform
- Industry
- Molecular Diagnostics
02
Partnerships
European Union H2020 research program grant recipient (#960327)Spin-off from Bellvitge Biomedical Research Institute (IDIBELL)Collaborations with academic institutions likely via IDIBELL connection.
Beyond the preview
Go deeper on ADmit Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADmit Therapeutics.